Pharmacologic Therapy for Pulmonary Arterial Hypertension in Adults

Article ID	Journal	Published Year	Pages	File Type
5954859	Chest	2014	27 Pages	PDF

Abstract

Clinical decisions regarding pharmacotherapy for PAH should be guided by high-level recommendations when sufficient evidence is available. Absent higher level evidence, consensus statements based upon available information must be used. Further studies are needed to address the gaps in available knowledge regarding optimal pharmacotherapy for PAH.

Keywords

EPC Guidelines Oversight Committee GOC ARIES FDA ETRA CTEPH mPAP IPAH AHRQ 6MWD RCT PDE5 BNP COI IOM PAH CCB 6-min walk distance Randomized controlled trial endothelin receptor antagonist Agency for Healthcare Research and Quality US Food and Drug Administration Cardiac output Conflict of interest World Health Organization PVR Phosphodiesterase-5 Pulmonary arterial hypertension mean pulmonary artery pressure Chronic thromboembolic pulmonary hypertension Calcium channel blocker Pulmonary vascular resistance Grade Institute of Medicine hazard ratio Pulmonary hypertension Idiopathic pulmonary arterial hypertension brain natriuretic peptide functional class WHO

Related Topics

Health Sciences Medicine and Dentistry Cardiology and Cardiovascular Medicine

Preview

Pharmacologic Therapy for Pulmonary Arterial Hypertension in Adults

Authors

Darren B. MD, PhD, FCCP, Joe MS, Lorinda MD, James R. MD, FCCP, Sandra PhD, Jess MD, Harold I. MD, FCCP, Stuart MD, FCCP, Namita MD, FCCP, Erika B. MD, Terence K. MD, FCCP, Rex MD, FCCP, C. Gregory MD, FCCP, David B. MD, FCCP,